{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:53:52Z","timestamp":1792601632604,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,2,3]],"date-time":"2021-02-03T00:00:00Z","timestamp":1612310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,3]],"date-time":"2021-02-03T00:00:00Z","timestamp":1612310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s15010-021-01577-x","type":"journal-article","created":{"date-parts":[[2021,2,3]],"date-time":"2021-02-03T08:03:47Z","timestamp":1612339427000},"page":"411-421","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Mono vs. combo regimens with novel beta-lactam\/beta-lactamase inhibitor combinations for the treatment of infections due to carbapenemase-producing Enterobacterales: insights from the literature"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8711-8305","authenticated-orcid":false,"given":"Simone","family":"Meini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Viaggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Tascini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,3]]},"reference":[{"key":"1577_CR1","doi-asserted-by":"publisher","first-page":"e01195","DOI":"10.1128\/AAC.01195-18","volume":"62","author":"A Stewart","year":"2018","unstructured":"Stewart A, Harris P, Henderson A, Paterson D. Treatment of infections by OXA-48-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2018;62:e01195-e1218.","journal-title":"Antimicrob Agents Chemother"},{"key":"1577_CR2","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1002\/phar.2210","volume":"39","author":"RL Crass","year":"2019","unstructured":"Crass RL, Pai MP. Pharmacokinetics and Pharmacodynamics of \u03b2-Lactamase Inhibitors. Pharmacotherapy. 2019;39:182\u201395.","journal-title":"Pharmacotherapy"},{"key":"1577_CR3","doi-asserted-by":"publisher","first-page":"e00115","DOI":"10.1128\/CMR.00115-20","volume":"34","author":"D Yahav","year":"2020","unstructured":"Yahav D, Giske CG, Gr\u0101matniece A, Abodakpi H, Tam VH, Leibovici L. New \u03b2-Lactam-\u03b2-Lactamase inhibitor combinations. Clin Microbiol Rev. 2020;34:e00115-e120.","journal-title":"Clin Microbiol Rev"},{"key":"1577_CR4","doi-asserted-by":"crossref","unstructured":"David 2019) David S, Reuter S, Harris SR, Glasner C, Feltwell T, Argimon S, et al. EuSCAPE Working Group; ESGEM Study Group, Feil EJ, Rossolini GM, Aanensen DM, Grundmann H. Epidemic of carbapenem-resistant Klebsiella pneumoniae in Europe is driven by nosocomial spread. Nat Microbiol. 2019;4:1919\u20131929","DOI":"10.1038\/s41564-019-0492-8"},{"key":"1577_CR5","doi-asserted-by":"crossref","unstructured":"Guti\u00e9rrez-Guti\u00e9rrez B, Salamanca E, de Cueto M, et al; REIPI\/ESGBIS\/ INCREMENT Investigators. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infect Dis 2017;17:726\u201334","DOI":"10.1016\/S1473-3099(17)30521-2"},{"key":"1577_CR6","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1093\/cid\/ciy492","volume":"68","author":"M Tumbarello","year":"2019","unstructured":"Tumbarello M, Trecarichi EM, Corona A, De Rosa FG, Bassetti M, Mussini C, et al. Efficacy of Ceftazidime\u2013avibactam Salvage Therapy in Patients With Infections Caused by Klebsiella pneumoniae Carbapenemase-producing K. pneumoniae. Clin Infect Dis. 2019;68:355\u201364.","journal-title":"Clin Infect Dis."},{"key":"1577_CR7","doi-asserted-by":"crossref","unstructured":"Tavoschi L, Forni S, Porretta A, Righi L, Pieralli F, Menichetti F, et al. On Behalf Of The Tuscan Clinical Microbiology Laboratory Network. Prolonged outbreak of New Delhi metallo-beta-lactamase-producing carbapenem-resistant Enterobacterales (NDM-CRE), Tuscany, Italy, 2018 to 2019. Euro Surveill. 2020;25:2000085.","DOI":"10.2807\/1560-7917.ES.2020.25.6.2000085"},{"key":"1577_CR8","doi-asserted-by":"crossref","unstructured":"Bassetti M, Giacobbe DR, Giamarellou H, Viscoli C, Daikos GL, Dimopoulos G, et al.; Critically Ill Patients Study Group of the European Society of Clinical Microbiology and Infectious Disease (ESCMID); Hellenic Society of Chemotherapy (HSC) and Societ\u00e0 Italiana di Terapia Antinfettiva (SITA). Management of KPC-producing Klebsiella pneumoniae infections. Clin Microbiol Infect. 2018;24:133\u2013144","DOI":"10.1016\/j.cmi.2017.08.030"},{"key":"1577_CR9","doi-asserted-by":"publisher","first-page":"e00079","DOI":"10.1128\/CMR.00079-17","volume":"31","author":"J Rodr\u00edguez-Ba\u00f1o","year":"2018","unstructured":"Rodr\u00edguez-Ba\u00f1o J, Guti\u00e9rrez-Guti\u00e9rrez B, Machuca I, Pascual A. Treatment of infections caused by extended-spectrum-beta-lactamase-, AmpC-, and Carbapenemase-producing Enterobacteriaceae. Clin Microbiol Rev. 2018;31:e00079-e117.","journal-title":"Clin Microbiol Rev"},{"key":"1577_CR10","doi-asserted-by":"crossref","unstructured":"Doi Y. Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections. Clin Infect Dis. 2019;9:565-575","DOI":"10.1093\/cid\/ciz830"},{"key":"1577_CR11","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1093\/cid\/ciw636","volume":"63","author":"RK Shields","year":"2016","unstructured":"Shields RK, Potoski BA, Haidar G, Hao B, Doi Y, Chen L, et al. Clinical outcomes, drug toxicity, and emergence of ceftazidime\u2013avibactam resistance among patients treated for carbapenem-resistant enterobacteriaceae infections. Clin Infect Dis. 2016;63:1615\u20138.","journal-title":"Clin Infect Dis."},{"key":"1577_CR12","first-page":"e00883","volume":"61","author":"RK Shields","year":"2017","unstructured":"Shields RK, Nguyen MH, Chen L, Press EG, Potoski BA, Marini RV, et al. Ceftazidime\u2013avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia. Antimicrob Agents Chemother. 2017;61:e00883-e917.","journal-title":"Antimicrob Agents Chemother"},{"key":"1577_CR13","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.ijantimicag.2017.01.018","volume":"49","author":"F Krapp","year":"2017","unstructured":"Krapp F, Grant JL, Sutton SH, Ozer EA, Barr VO. Treating complicated carbapenem-resistant enterobacteriaceae infections with ceftazidime\/avibactam: a retrospective study with molecular strain characterisation. Int J Antimicrob Agents. 2017;49:770\u20133.","journal-title":"Int J Antimicrob Agents"},{"key":"1577_CR14","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ijid.2017.03.021","volume":"59","author":"JJ Cast\u00f3n","year":"2017","unstructured":"Cast\u00f3n JJ, Lacort-Peralta I, Mart\u00edn-D\u00e1vila P, Loeches B, Tabares S, Temkin L, et al. Clinical efficacy of ceftazidime\/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients. Int J Infect Dis. 2017;59:118\u201323.","journal-title":"Int J Infect Dis"},{"key":"1577_CR15","doi-asserted-by":"crossref","unstructured":"Temkin E, Torre-Cisneros J, Beovic B, Benito N, Giannella M, Gilarranz R, et al. Ceftazidime\u2013avibactam as Salvage Therapy for Infections Caused by Carbapenem-Resistant Organisms. Antimicrob Agents Chemother. 2017;61","DOI":"10.1128\/AAC.01964-16"},{"key":"1577_CR16","doi-asserted-by":"crossref","unstructured":"King M, Heil E, Kuriakose S, Bias T, Huang V, El-Beyrouty C, et al. Multicenter Study of Outcomes with Ceftazidime\u2013avibactam in Patients with Carbapenem-Resistant Enterobacteriaceae Infections. Antimicrob Agents Chemother. 2017;61","DOI":"10.1128\/AAC.00449-17"},{"key":"1577_CR17","doi-asserted-by":"crossref","unstructured":"Shields RK, Nguyen MH, Chen L, Press EG, Kreiswirth BN, Clancy CJ. Pneumonia and renal replacement therapy are risk factors for ceftazidime\u2013avibactam treatment failures and resistance among patients with carbapenem-resistant Enterobacteriaceae infections. Antimicrob Agents Chemother 2018; 62. pii: e02497\u201317","DOI":"10.1128\/AAC.02497-17"},{"key":"1577_CR18","doi-asserted-by":"publisher","first-page":"3170","DOI":"10.1093\/jac\/dky295","volume":"73","author":"A Sousa","year":"2018","unstructured":"Sousa A, P\u00e9rez-Rodr\u00edguez MT, Soto A, Rodr\u00edguez L, P\u00e9rez-Landeiro A, Mart\u00ednez-Lamas L, et al. Effectiveness of ceftazidime\/avibactam as salvage therapy for treatment of infections due to OXA-48 carbapenemase-producing Enterobacteriaceae. J Antimicrob Chemother. 2018;73:3170\u20135.","journal-title":"J Antimicrob Chemother"},{"key":"1577_CR19","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.ijantimicag.2018.11.015","volume":"53","author":"C De la Calle","year":"2019","unstructured":"De la Calle C, Rodr\u00edguez O, Morata L, Marco F, Cardozo C, Garc\u00eda-Vidal C, et al. Clinical characteristics and prognosis of infections caused by OXA-48 carbapenemase-producing Enterobacteriaceae in patients treated with ceftazidime\u2013avibactam. Int J Antimicrob Agents. 2019;53:520\u20134.","journal-title":"Int J Antimicrob Agents"},{"key":"1577_CR20","doi-asserted-by":"publisher","first-page":"e02313","DOI":"10.1128\/AAC.02313-19","volume":"64","author":"R Ackley","year":"2020","unstructured":"Ackley R, Roshdy D, Meredith J, Minor S, Anderson WE, Capraro GA, Polk C. Meropenem\u2013vaborbactam versus ceftazidime\u2013avibactam for treatment of carbapenem-resistant enterobacteriaceae infections. Antimicrob Agents Chemother. 2020;64:e02313-e2319.","journal-title":"Antimicrob Agents Chemother"},{"key":"1577_CR21","doi-asserted-by":"crossref","unstructured":"van Duin D, Lok JJ, Earley M, Cober E, Richter SS, Perez F, et al. Antibacterial Resistance Leadership Group. Colistin Versus Ceftazidime\u2013avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae. Clin Infect Dis. 2018; 66:163\u2013171","DOI":"10.1093\/cid\/cix783"},{"key":"1577_CR22","doi-asserted-by":"publisher","first-page":"e00528","DOI":"10.1128\/AAC.00528-19","volume":"63","author":"T Guimar\u00e3es","year":"2019","unstructured":"Guimar\u00e3es T, Nou\u00e9r SA, Martins RCR, Perdig\u00e3o Neto LV, Martins WMBS, et al. Ceftazidime\/avibactam as salvage therapy for infections caused by Enterobacteriales co-resistant to carbapenems and polymyxins. Antimicrob Agents Chemother. 2019;63:e00528-e619.","journal-title":"Antimicrob Agents Chemother"},{"key":"1577_CR23","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.ijantimicag.2019.08.025","volume":"54","author":"L Onorato","year":"2019","unstructured":"Onorato L, Di Caprio G, Signoriello S, Coppola N. Efficacy of ceftazidime\/avibactam in monotherapy or combination therapy against carbapenem-resistant Gram-negative bacteria: A meta-analysis. Int J Antimicrob Agents. 2019;54:735\u201340.","journal-title":"Int J Antimicrob Agents"},{"key":"1577_CR24","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s40121-018-0214-1","volume":"7","author":"RG Wunderink","year":"2018","unstructured":"Wunderink RG, Giamarellos-Bourboulis EJ, Rahav G, Mathers AJ, Bassetti M, Vazquez J, et al. Effect and safety of meropenem\u2013vaborbactam versus best-available therapy in patients with carbapenem-resistant Enterobacteriaceae infections: The TANGO II Randomized Clinical Trial. Infect Dis Ther. 2018;7:439\u201355.","journal-title":"Infect Dis Ther"},{"key":"1577_CR25","doi-asserted-by":"crossref","unstructured":"Motsch J, Murta de Oliveira C, Stus V, K\u00f6ksal I, Lyulko O, Boucher HW, et al. RESTORE-IMI 1: A multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem\/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections. Clin Infect Dis. 2020;70:1799\u20131808.","DOI":"10.1093\/cid\/ciz530"},{"key":"1577_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijid.2017.09.017","volume":"65","author":"P Gaibani","year":"2017","unstructured":"Gaibani P, Lewis RE, Volpe SL, Giannella M, Campoli C, Landini MP, et al. In vitro interaction of ceftazidime\u2013avibactam in combination with different antimicrobials against KPC-producing Klebsiella pneumoniae clinical isolates. Int J Infect Dis. 2017;65:1\u20133.","journal-title":"Int J Infect Dis"},{"key":"1577_CR27","doi-asserted-by":"crossref","unstructured":"Shields RK, Nguyen MH, Hao B, Kline EG, Clancy CJ. Colistin Does Not Potentiate Ceftazidime\u2013avibactam Killing of Carbapenem-Resistant Enterobacteriaceae In Vitro or Suppress Emergence of Ceftazidime\u2013avibactam Resistance. Antimicrob Agents Chemother. 2018;62","DOI":"10.1128\/AAC.01018-18"},{"key":"1577_CR28","doi-asserted-by":"crossref","unstructured":"Chew KL, Tay MKL, Cheng B, Lin RTP, Octavia S, Teo JWP. Aztreonam-Avibactam Combination Restores Susceptibility of Aztreonam in Dual-Carbapenemase-Producing Enterobacteriaceae. Antimicrob Agents Chemother. 2018; 27;62:18","DOI":"10.1128\/AAC.00414-18"},{"key":"1577_CR29","first-page":"e01426","volume":"63","author":"M Biagi","year":"2019","unstructured":"Biagi M, Wu T, Lee M, Patel S, Butler D, Wenzler E. Searching for the Optimal Treatment for Metallo- and Serine-\u03b2-Lactamase Producing Enterobacteriaceae: Aztreonam in Combination with Ceftazidime\u2013avibactam or Meropenem\u2013vaborbactam. Antimicrob Agents Chemother. 2019;63:e01426-e1519.","journal-title":"Antimicrob Agents Chemother"},{"key":"1577_CR30","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1093\/jac\/dkx393","volume":"73","author":"A Jayol","year":"2018","unstructured":"Jayol A, Nordmann P, Poirel L, Dubois V. Ceftazidime\/avibactam alone or in combination with aztreonam against colistin-resistant and carbapenemase-producing Klebsiella pneumoniae. J Antimicrob Chemother. 2018;73:542\u20134.","journal-title":"J Antimicrob Chemother"},{"key":"1577_CR31","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1093\/jac\/dkx419","volume":"73","author":"S Nath","year":"2018","unstructured":"Nath S, Moussavi F, Abraham D, Landman D, Quale J. In vitro and in vivo activity of single and dual antimicrobial agents against KPC-producing Klebsiella pneumoniae. J Antimicrob Chemother. 2018;73:431\u20136.","journal-title":"J Antimicrob Chemother"},{"key":"1577_CR32","doi-asserted-by":"publisher","first-page":"3211","DOI":"10.1093\/jac\/dkz330","volume":"74","author":"S G\u00f6ttig","year":"2019","unstructured":"G\u00f6ttig S, Frank D, Mungo E, Nolte A, Hogardt M, Besier S, Wichelhaus TA. Emergence of ceftazidime\/avibactam resistance in KPC-3-producing Klebsiella pneumoniae in vivo. J Antimicrob Chemother. 2019;74:3211\u20136.","journal-title":"J Antimicrob Chemother"},{"key":"1577_CR33","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1089\/mdr.2018.0234","volume":"25","author":"D Ojdana","year":"2019","unstructured":"Ojdana D, Gutowska A, Sacha P, Majewski P, Wieczorek P, Tryniszewska E. Activity of ceftazidime\u2013avibactam alone and in combination with ertapenem, fosfomycin, and tigecycline against carbapenemase-producing Klebsiella pneumoniae. Microb Drug Resist. 2019;25:1357\u201364.","journal-title":"Microb Drug Resist"},{"key":"1577_CR34","doi-asserted-by":"crossref","unstructured":"Mikhail S, Singh NB, Kebriaei R, Rice SA, Stamper KC, Castanheira M, Rybak MJ. Evaluation of the Synergy of Ceftazidime\u2013avibactam in Combination with Meropenem, Amikacin, Aztreonam, Colistin, or Fosfomycin against Well-Characterized Multidrug-Resistant Klebsiella pneumoniae and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2019;63. pii: e00779\u201319","DOI":"10.1128\/AAC.00779-19"},{"key":"1577_CR35","doi-asserted-by":"publisher","first-page":"105852","DOI":"10.1016\/j.ijantimicag.2019.11.009","volume":"55","author":"J Borjan","year":"2020","unstructured":"Borjan J, Meyer KA, Shields RK, Wenzler E. Activity of ceftazidime\u2013avibactam alone and in combination with polymyxin B against carbapenem-resistant Klebsiella pneumoniae in a tandem in vitro time-kill\/in vivo Galleria mellonella survival model analysis. Int J Antimicrob Agents. 2020;55:105852.","journal-title":"Int J Antimicrob Agents"},{"key":"1577_CR36","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1126\/science.aay3041","volume":"367","author":"J Liu","year":"2020","unstructured":"Liu J, Gefen O, Ronin I, Bar-Meir M, Balaban NQ. Effect of tolerance on the evolution of antibiotic resistance under drug combinations. Science. 2020;367:200\u20134.","journal-title":"Science"},{"key":"1577_CR37","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.1128\/AAC.02638-15","volume":"60","author":"RK Shields","year":"2016","unstructured":"Shields RK, Clancy CJ, Press EG, Nguyen MH. Aminoglycosides for Treatment of bacteremia due to carbapenem-resistant Klebsiella pneumoniae. Antimicrob Agents Chemother. 2016;60:3187\u201392.","journal-title":"Antimicrob Agents Chemother"},{"key":"1577_CR38","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jgar.2019.12.009","volume":"22","author":"Y Wang","year":"2020","unstructured":"Wang Y, Wang J, Wang R, Cai Y. Resistance to ceftazidime\u2013avibactam and underlying mechanisms. J Glob Antimicrob Resist. 2020;22:18\u201327.","journal-title":"J Glob Antimicrob Resist"},{"key":"1577_CR39","first-page":"e02590","volume":"62","author":"WW Nichols","year":"2018","unstructured":"Nichols WW, Stone GG, Newell P, Broadhurst H, Wardman A, MacPherson M, et al. Ceftazidime- Avibactam Susceptibility Breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2018;62:e02590-e2617.","journal-title":"Antimicrob Agents Chemother"},{"key":"1577_CR40","doi-asserted-by":"crossref","unstructured":"Gaudereto JJ, Perdig\u00e3o Neto LV, Leite GC, Ruedas Martins R, Boas do Prado GV, Rossi F, et al. Synergistic Effect of Ceftazidime\u2013avibactam with Meropenem against Panresistant, Carbapenemase-Harboring Acinetobacter baumannii and Serratia marcescens Investigated Using Time-Kill and Disk Approximation Assays. Antimicrob Agents Chemother. 2019;63. pii: e02367\u201318","DOI":"10.1128\/AAC.02367-18"},{"key":"1577_CR41","doi-asserted-by":"crossref","unstructured":"Shields RK, Chen L, Cheng S, Chavda KD, Press EG, Snyder A, et al. Emergence of Ceftazidime\u2013avibactam Resistance Due to Plasmid-Borne blaKPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections. Antimicrob Agents Chemother. 2017;61","DOI":"10.1128\/AAC.02097-16"},{"key":"1577_CR42","doi-asserted-by":"crossref","unstructured":"Marshall S, Hujer AM, Rojas LJ, Papp-Wallace KM, Humphries RM, Spellberg B et al. Can Ceftazidime\u2013avibactam and Aztreonam Overcome \u03b2-Lactam Resistance Conferred by Metallo-\u03b2-Lactamases in Enterobacteriaceae? Antimicrob Agents Chemother. 2017;61. pii: e02243\u201316.","DOI":"10.1128\/AAC.02243-16"},{"key":"1577_CR43","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s12866-017-1012-8","volume":"17","author":"AU Khan","year":"2017","unstructured":"Khan AU, Maryam L, Zarrilli R. Structure, Genetics and Worldwide Spread of New Delhi Metallo-\u03b2-lactamase (NDM): a threat to public health. BMC Microbiol. 2017;17:101.","journal-title":"BMC Microbiol"},{"key":"1577_CR44","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s15010-019-01291-9","volume":"47","author":"S Meini","year":"2019","unstructured":"Meini S, Tascini C, Cei M, Sozio E, Rossolini GM. AmpC \u03b2-lactamase-producing Enterobacterales: what a clinician should know. Infection. 2019;47:363\u201375.","journal-title":"Infection"}],"updated-by":[{"DOI":"10.1007\/s15010-021-01596-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T00:00:00Z","timestamp":1616112000000}}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-021-01577-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-021-01577-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-021-01577-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T22:12:56Z","timestamp":1627683176000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-021-01577-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,3]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["1577"],"URL":"https:\/\/doi.org\/10.1007\/s15010-021-01577-x","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s15010-021-01596-8","asserted-by":"object"}]},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,3]]},"assertion":[{"value":"22 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s15010-021-01596-8","URL":"https:\/\/doi.org\/10.1007\/s15010-021-01596-8","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}}]}}